Posts by: Joana Carvalho

Joana Carvalho

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

February 18, 2021February 18, 2021

Potential Therapy May Better Prepare Older Patients Before Stem Cell Transplant

News

JSP191, an investigational therapy by Jasper Therapeutics, showed promising efficacy as a conditioning agent to prepare older patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) for a stem ... Read more

February 11, 2021February 11, 2021

Eprenetapopt-Azacitidine Combo Shows Promise for AML With TP53 Mutations

News

Eprenetapopt (APR-246), Aprea Therapeutics’ lead cancer therapy candidate, was well-tolerated and showed promising clinical activity when given alongside azacitidine to treat patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia ... Read more

February 8, 2021February 8, 2021

Xospata Conditionally Approved in China for Certain Acute Myeloid Leukemias

News

Xospata (gilteritinib) has been conditionally approved in China to treat adults who have relapsed or refractory acute myeloid leukemia (AML) with mutations in the FLT3 gene. The therapy’s conditional approval ... Read more

December 17, 2020December 17, 2020

Venclexta Combos Approved in Canada to Treat Newly Diagnosed AML

News

Health Canada has approved Venclexta (venetoclax) in combination with Vidaza (azacitidine) or low-dose cytarabine to treat newly diagnosed adults, ages 75 and older, with acute myeloid leukemia (AML), who have other ... Read more

December 14, 2020December 17, 2020

Potential Cancer Vaccine DCP-001 May Control AML Residual Disease

News

DCP-001, the lead cancer vaccine candidate by DCprime, safely elicited a tumor-specific immune response in patients with acute myeloid leukemia (AML), who still showed signs of residual disease despite having ... Read more

November 12, 2020November 12, 2020

FDA Grants Orphan Drug Designation to Immune-Onc’s IO-202

News

The U.S. Food and Drug Administration (FDA) has given the designation of orphan drug to Immune-Onc Therapeutics’ investigational antibody-based therapy IO-202 for the treatment of acute myeloid leukemia (AML). Orphan ... Read more

October 15, 2020October 15, 2020

Omidubicel Shows Further Trial Benefits for Marrow Transplants in AML, Other Cancers

News

Omidubicel, an experimental cell therapy for blood cancer patients needing a bone marrow transplant, is superior to standard umbilical cord blood transplant at increasing the proportion of patients achieving normal platelet counts within ... Read more

October 8, 2020October 8, 2020

Phase 1 Trial Finishes Dosing 1st AML Patient Group With Actimab-A Plus Venclexta

News

The first group of patients with relapsed or refractory acute myeloid leukemia (AML) has been dosed in a Phase 1/2 dose-escalation trial assessing the safety and efficacy of Actimab-A and Venclexta (venetoclax) ... Read more

September 21, 2020September 21, 2020

Rigosertib Combo Fails to Prolong Survival in Higher-risk Myelodysplastic Syndromes

News

When given alongside best supportive care, rigosertib failed to prolong the survival of patients with higher-risk myelodysplastic syndromes (HR-MDS), a group of blood cancers that often progress to acute myeloid ... Read more

August 31, 2020August 31, 2020

Idhifa Combo Fails to Prolong Survival in Older Patients in Phase 3 Trial

News

Idhifa (enasidenib), given alongside best supportive care, failed to prolong overall survival of older adults with relapsed or refractory acute myeloid leukemia (AML) carrying a mutation in the IDH2 gene, ... Read more